Navigation Links
USPTO Issues Patent for CardioGenics' Signal Amplification Technology
Date:6/29/2011

MISSISSAUGA, Ontario, June 29, 2011 /PRNewswire/ -- CardioGenics Holdings Inc. (CGNH.OB) announced today that the United States Patent & Trademark Office (USPTO) has notified the company that its patent application has been granted (issued patent # 7,964,415). This patent covers CardioGenics Inc.'s proprietary signal amplification technology, which is a key component of the core technology for CardioGenics' Ultra-Sensitive QL Care™ Analyzer. CardioGenics' unique methodology for signal amplification enables a decrease in the amount of binding reagents used in immunoassay diagnostic tests, such as those to be performed on the QL Care™ Analyzer, which, in turn, results in improved signal-to-noise ratio thereby increasing testing sensitivity.

"We are very pleased that the USPTO has recognized the unique nature of CardioGenics' signal amplification technology," said Dr. Yahia Gawad, CEO of CardioGenics. "This patent is an important addition to our patent portfolio since it addresses a key component of the technology that permits the ultra-sensitive performance of our QL Care™ Analyzer," continued Dr. Gawad.

About CardioGenics Holdings Inc.

Through its operating subsidiaries, the Company develops ultra-sensitive analyzers and other products targeting the immunoassay segment of the Point-Of-Care IVD testing market. It has developed the QL Care™ Analyzer, a proprietary and ultra-sensitive Point-Of-Care immuno-analyzer, which will run a number of diagnostic tests under development, the first of which will be a series of cardiovascular diagnostic tests. As part of its core proprietary technology, the Company has also developed a proprietary method for silver coating paramagnetic microspheres (a fundamental platform component of immunoassay equipment), which improve instrument sensitivity to light. The Company's proprietary microspheres technology and SAVAsphere magnetic beads are developed
'/>"/>

SOURCE CardioGenics Holdings Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Shrink Nanotechnologies Announces That Critical Cell Align Tissue Engineering Platform Patent as Well as IP on a Novel Immunoassay Substrate Material Has Been Filed With the USPTO
2. USPTO Allows NivaSonix Core Patent - External Ultrasound Lipoplasty
3. KemPharm, Inc. Receives Notice of Issuance from USPTO on Second Patent Protecting Companys ADHD Prodrug Technology
4. KemPharm, Inc. Receives Notice of Issuance From USPTO on Patent Protecting Companys ADHD Prodrug Technology
5. Endo Pharmaceuticals Issues Voluntary, Nationwide Recall of Two Lots of Endocet® (Oxycodone/Acetaminophen, USP) Tablets, 10 Mg /325 Mg
6. Preliminary Results of a Large Scale Study Show ConvaTec Moldable Technology™ Skin Barriers Help to Prevent and Improve Peristomal Skin Issues in Ostomy Patients
7. Health Information Technology: UC San Diego New Seminar Explores Four Critical Issues
8. FDA Issues Draft Guidance for Early Version of an Artificial Pancreas System
9. Amylin Pharmaceuticals Issues Statement Regarding U.S. District Court Order
10. United Kingdoms National Institute for Health and Clinical Excellence Issues Guidance on Percutaneous Tibial Nerve Stimulation for Faecal Incontinence
11. BD Issues 2010 Sustainability Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... PLAINFIELD, N.J. , Aug. 1, 2014  PTC ... that on July 31, 2014 it approved non-statutory stock ... its common stock to seven new employees. The awards ... as a component of our new hires, employment compensation. ... Compensation Committee on July 31, 2014 and are being ...
(Date:8/1/2014)... , Aug. 1, 2014  With monumental health ... to speak a second language. Clinical efficacy is no ... established under the ACA like PCORI are directing roughly ... variety of new entities and environments, the federal healthcare ... the new language of outcomes and managed markets to ...
(Date:8/1/2014)... and NEW YORK , ... VRX) and Pershing Square Capital Management, L.P. today responded ... Inc. (NYSE: AGN ) in California.  The ... regarding the tender offer rules.  Allergan,s ... to interfere with shareholders, efforts to call a special ...
Breaking Medicine Technology:PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 2Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 3Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 4Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 5Valeant Pharmaceuticals And Pershing Square Respond To Frivolous Allergan Lawsuit 6
... Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) ... ) and Cephalon, Inc. (NASADQ: CEPH) on their announcement that ... to the news, Valeant has withdrawn its consent solicitation. ... for Cephalon stockholders and we are pleased that Teva has ...
... Solutions, Inc. (OTCQB: VHSLD) announced that it will begin ... Financial Industry Regulatory Authority has approved a change in ... ticker change has gone into effect for the trading ... the "D" will be removed from the ticker symbol ...
Cached Medicine Technology:Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2Vertical Health Solutions to Begin Doing Business as OnPoint Medical Diagnostics and Announces Completion of Symbol Change 2
(Date:8/1/2014)... Recently, iFitDress.com, one of the most famous ... of top bridesmaid dresses online. At the moment, ... up to 52% off. According to the company’s senior spokesman, ... , The company’s stock is limited. Those who are ... store as soon as possible. All its products are delicately ...
(Date:8/1/2014)... 2014 Cannabis use among young people has ... to 17 having used marijuana at least once and 17 ... “Say ‘No’ to Drugs, Say ‘Yes to Life,’ volunteers from ... youth this summer with factual information about drugs, to help ... Hamburg “Say ‘No’ to Drugs, Say ‘Yes’ to Life,” volunteers ...
(Date:8/1/2014)... 2014 The Judicial Panel on Multidistrict ... replacement therapy caused strokes, heart attacks, and other injuries ... Matthew F. Kennelly as the transferee judge and ordered ... Chicago-based federal court. , As one of his first ... committees of attorneys who will move the litigation forward ...
(Date:8/1/2014)... San Diego School of Medicine report that dietary capsaicin ... chronic activation of a receptor on cells lining the ... the risk of colorectal tumors. , The findings are ... The Journal of Clinical Investigation . , The receptor ... sensory neurons, where it acts as a sentinel for ...
(Date:8/1/2014)... in St. Louis helps explain why brain tumors occur ... than similar tumors in females. For example, glioblastomas, the ... often in males, who suffer greater cognitive impairments than ... researchers found that retinoblastoma protein (RB), a protein known ... male brain cells than in female brain cells. , ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Top Bridesmaid Dresses For The Global Customers 2Health News:Addressing a Serious Issue Affecting German Teens 2Health News:Judge Kennelly Appoints Attorney Michelle Kranz to the Plaintiffs’ Executive Committee in the Testosterone Replacement Therapy MDL 2Health News:Pepper and halt: Spicy chemical may inhibit gut tumors 2Health News:Study reveals one reason brain tumors are more common in men 2
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
... www.stressballsuk.com ... points to an economic upturn and possibly the beginning of the end of the credit ... (PRWEB) March 2, ... to an economic upturn and possibly the beginning of the end of the credit crunch., ...
... ... event focusing on insights into the exploding field of neuroscience, what this means for ... the most effective ways to motivate and generate transformation in organisations – all leading ... ...
... ... to fill the gap in poor physician adherence to low back pain management guidelines with the ... ... for the iPhone platform this week to help bridge an expensive health care gap. The ...
Cached Medicine News:Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 2Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 3Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 4Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 5Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 6Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 7Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 8Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 9Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 10Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 11Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 12Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 13Health News:MAP Pharmaceuticals Reports 2009 Fourth Quarter and Year End Financial Results 14Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 2Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 3Health News:Dental Operatory Equipment and Practice Management Software Market in the U.S. to Reach Almost $2 Billion by 2016 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 2Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 3Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 4Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 5Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 6Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 7Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 8Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 9Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 10Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 11Health News:Archimedes Pharma Announces Major Fund Raising of GBP65 Million 12Health News:Promotional Stress Ball Supplier -- StressBallsUK.com Starts 2010 Strongest Ever 2Health News:Key Leadership Seminar: Maximizing Profit through Social Intelligence - What Neuroscience Tells Us 2Health News:Clinically Relevant Technologies Releases New Medical iPhone App To Fill Gap In Adherence To Low Back Pain Management Guidelines 2
Designed for use during surgical procedures under fluoroscopy. A very practical unit, the frames superior design eliminates problems associated with imaging....
Low temp, micro fine tip, patented Aaron RAM cauteries....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: